News
SDZXF
90.45
NaN%
--
Sandoz creates biosimilar unit to benefit from major patent cliff
Seeking Alpha · 8h ago
Sandoz reshapes biosimilar and generics leadership to seize upcoming patent cliff
TipRanks · 17h ago
Sandoz appoints Armin Metzger as President of Biosimilar Development, Manufacturing & Supply
Reuters · 18h ago
Analysts Are Bullish on Top Healthcare Stocks: Sandoz Group Ltd (SDZXF), Roche Holding AG (RHHVF)
TipRanks · 4d ago
Berenberg Bank Sticks to Their Hold Rating for Sandoz Group Ltd (SDZXF)
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Sandoz Group Ltd (OtherSDZXF)
TipRanks · 02/27 01:40
Sandoz downgraded to Hold from Buy at Deutsche Bank
TipRanks · 02/26 22:35
Sandoz downgraded to Equal Weight from Overweight at Barclays
TipRanks · 02/26 09:35
Barclays downgrades Sandoz Group Ltd (SDZXF) to a Hold
TipRanks · 02/26 07:25
Sandoz lifts profit, dividend and 2026 outlook on biosimilar-driven growth
TipRanks · 02/25 06:33
Sandoz Group AG Publishes Transcript of FY 2025 Results Analyst Call
Reuters · 02/25 06:06
Sandoz FY 2025 management free cash flow jumps 39% to USD 1.5 billion
Reuters · 02/25 06:01
BRIEF-Sandoz FY Sales USD 11,100 Million Vs. IBES Estimate USD 11,079 Million
Reuters · 02/25 06:01
Sandoz confirms E.C. granted marketing authorization for Ranluspec
TipRanks · 02/23 11:38
Sandoz wins EU approval for Ranluspec biosimilar, bolstering ophthalmology push
TipRanks · 02/23 10:33
European Commission approves Sandoz Ranluspec ranibizumab biosimilar
Reuters · 02/23 10:00
Jefferies Sticks to Its Buy Rating for Sandoz Group Ltd (SDZXF)
TipRanks · 02/20 15:35
Kepler Capital Sticks to Its Buy Rating for Sandoz Group Ltd (SDZXF)
TipRanks · 02/20 01:48
Sandoz receives U.S. FDA approval to expand Enzeevu label
TipRanks · 02/18 11:55
Sandoz wins FDA nod to expand Enzeevu label to multiple retinal indications
Seeking Alpha · 02/18 10:09
More
Webull provides a variety of real-time SDZXF stock news. You can receive the latest news about Sandoz Group AG through multiple platforms. This information may help you make smarter investment decisions.
About SDZXF
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.